Follicular Lymphoma

Questions discussed in this category

What are your top takeaways in Hematologic Malignancies from ASH 2024?

12 Answers available

What are your top takeaways in Lymphoma from ASH 2025?

3 Answers available

What is your approach to managing follicular lymphoma with central nervous system involvement?

Have you treated such cases with systemic therapies? If so, which ones (e.g., cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, or targeted age...

1 Answer available

When would you consider treating an asymptomatic patient with follicular lymphoma?

Are there characteristics which could help identify whether a follicular lymphoma might behave more indolently vs aggressively and inform treatment se...

4 Answers available

How do you choose between axicabtagene ciloleucel and tisagenlecleucel in patients with follicular lymphoma for whom you are recommending CAR T-cell therapy?

2 Answers available

What factors do you consider when sequencing bispecific T-cell engaging antibodies and CAR T-cell therapies for the treatment of follicular lymphoma?

1 Answer available

Would you recommend allogeneic stem cell transplantation for consolidation in a patient with follicular lymphoma who relapsed within 13 months of initial chemo-immunotherapy?

2 Answers available

Papers discussed in this category

Blood, 2013-08-08

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

British journal of haematology, 2016-03

Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-10

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Cancer, 2023 Jun 24

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Lancet (London, England), 2025 Dec 07

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Lancet (London, England), 2025 Dec 05

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

The New England journal of medicine, 2025 Dec 06

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Related Topics